AstraZeneca PLC AstraZeneca announces sale of West Chester site
RNS Number : 9775H
30 November 2022
30 November 2022 07:05 GMT
AstraZeneca announces sale of its West Chester, Ohio (US)
National Resilience, Inc. to expand site and support future
growth of its medicines manufacturing capabilities
AstraZeneca today announces the sale of its West Chester site in
Ohio, US, to National Resilience, Inc. (Resilience), a
technology-focused manufacturing company dedicated to broadening
access to complex medicines.
Andrew Wirths, Senior Vice President, Americas Supply Region,
AstraZeneca, said: "As part of our long-term strategy to ensure our
global supply network remains fit for the future, we are
continuously optimising our manufacturing footprint to meet the
evolving needs of our pipeline and portfolio. The transfer of our
West Chester site to Resilience will enable the continued supply of
AstraZeneca medicines to patients, as well as the continued
employment for more than 500 people working at the West Chester
site. I'm encouraged by Resilience's plans to transform the site
into their drug product centre of excellence."
"The West Chester site will play an important role in the
delivery of our mission to broaden access to complex medicines,
protect biopharmaceutical supply chains, and strengthen domestic
preparedness," said Rahul Singhvi, Sc.D, Chief Executive Officer of
Resilience. "I'm confident that West Chester's premier
capabilities, including the talented employees who are joining
Resilience, will help us expand our business in new
AstraZeneca expects to complete the sale in the first quarter of
2023, with a phased transition of services.
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development, and commercialisation of prescription medicines in
Oncology, Rare Diseases, and BioPharmaceuticals, including
Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca operates in over
100 countries and its innovative medicines are used by millions of
patients worldwide. Please visit astrazeneca.com and follow the
Company on Twitter @ AstraZeneca .
For details on how to contact the Investor Relations Team,
please click here . For Media contacts, click here .
Resilience is a technology-focused biomanufacturing company
dedicated to broadening access to complex medicines. Founded in
2020, the company is building a sustainable network of high-tech,
end-to-end manufacturing solutions to ensure the treatments of
today and tomorrow can be made quickly, safely, and at scale.
Resilience seeks to free its partners to focus on the discoveries
that improve patients' lives by continuously advancing the science
of biopharmaceutical manufacturing and development. For more
information, visit www.Resilience.com and follow us on social
media: @IncResilience on Twitter and Resilience on LinkedIn.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact email@example.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
(END) Dow Jones Newswires
November 30, 2022 02:05 ET (07:05 GMT)
Gráfico Histórico do Ativo
De Dez 2022 até Jan 2023
Gráfico Histórico do Ativo
De Jan 2022 até Jan 2023